The majority of Esmya^® patients experience both amenorrhoea and clinically significant fibroid reduction with at least 4 intermittent courses¹.
It is estimated that out of 100 women more than 95 would benefit from four intermittent treatment courses of Esmya^®1..
Percentage of patients with amenorrhoea and/or a clinically significant reduction (>=25%) in fibroid volume.

Adapted from Donnez 2015, in press
Full analysis set 1*
*All patients that received study treatment at least once for treatment course 1

Reference:

1.Donnez J, et al. 2015, in press. [PEARL IV, Part 2].

Esmya^® progressively reduces pain.
Median pain scores (VAS) were substantially decreased vs baseline at the end of each treatment course.
Women maintained the improvements in pain score, even in the off-treatment period.

Esmya^® progressively improves QoL related to UF symptoms¹.
UF symptom-related QoL was substantially improved vs. baseline at the end of each course¹.
Women maintained these improvements in QoL, even in the off-treatment period¹.

Esmya^® progressively shrinks fibroids, with reductions maintained even after treatment^1,2.

Esmya^® can help to correct anaemia¹.
With iron supplementation, anemia was eventually corrected in most patients on Placebo, Esmya^®(UPA 5 mg) and UPA 10 mg.

With Esmya^® amenorrhea rates were achieved rapidly over successive treatment courses.
Amenorrhea rates were achieved between 4 to 6 days after the start of each Esmya^® treatment course.

With Esmya^®, PBAC (Pictorial Bleeding Assessment Chart) showed a marked progressive reduction in menstrual bleeding. PBAC score is a method to quantify blood loss at women. PBAC scores > 100 indicates menorrhagia.

Esmya^® maintains bleeding control over successive treatment courses.
More than 90% of women had controlled bleeding* at the end of each treatment course.

Esmya^® maintains amenorrhoea over successive treatment courses.
More than 80% of women achieved amenorrhoea* by the end of the fourth course of Esmya^®.

The safety profile of Esmya® is supported by extensive clinical studies and real-life experience. The vast majority of adverse events during intermittent and pre-operative therapy with Esmya® were mild to moderate and resolved spontaneously ^7,44.

Menopausal-like adverse events decreased in frequency during intermittent therapy.
Hot flushes decreased from 5.7% to 2.8% between the first and fourth courses⁷.